What Comes After Semaglutide: The Next Generation of Metabolic Compounds

Why There Are Suddenly So Many

For most of its history this field had one idea: activate the GLP-1 receptor. Exenatide arrived in 2005, liraglutide followed, semaglutide refined it, and that was broadly the story. Then tirzepatide added a second receptor and outperformed the single-agonist standard, and the field concluded that combinations were the road forward. What followed was a rush of compounds each trying a different combination.

The shift, in plain language: imagine a workshop that had spent twenty years perfecting one tool. It worked, so the work went into making it sharper and more durable. Then someone tried using two tools at once and got a result the sharpest single tool could not match. Overnight the question stopped being "how good can this tool be" and became "which combination should we try". That is the moment this field is in now — and it is why the newer names look confusingly similar. They are all variations on which handful of receptors to engage together.

The Lineage

The compounds most people know sit in a clear order, and seeing it makes the newer arrivals easier to place.

Note that Survodutide and Mazdutide are not the same as Tirzepatide, despite all three being dual agonists. Tirzepatide pairs GLP-1 with GIP; both of the newer compounds pair it with glucagon instead. Same number of receptors, different second receptor, meaningfully different behaviour.

Survodutide and Mazdutide: The Glucagon Pair

Survodutide, developed by Boehringer Ingelheim, combines GLP-1 with glucagon receptor activation. Phase 3 data reported around 16.6% average weight reduction at 76 weeks against 3.2% for placebo, with roughly 85% of participants reaching at least a 5% reduction. It is also being studied in metabolic liver disease, which is where the glucagon component is of particular interest.

Mazdutide takes a similar receptor approach from a different structural starting point — it is an oxyntomodulin analogue, whereas survodutide is derived from human glucagon. It was approved in China in June 2025 for chronic weight management, making it one of the first glucagon-containing dual agonists approved anywhere.

Why glucagon keeps appearing, in plain language: GLP-1 and GIP both work on the intake side — appetite, satiety, insulin response. They are all about what comes in. Glucagon acts on the other side of the ledger: energy expenditure, and how the liver handles fat. Adding it is the difference between managing a household budget by spending less and managing it by also earning more. That is why glucagon appears in survodutide, mazdutide and retatrutide alike — it is the field’s current answer to the main limitation of the single-agonist generation.

Bimagrumab: The One That Is Not Like the Others

Bimagrumab does not belong to the incretin family at all. It is a monoclonal antibody targeting the activin type II receptor, and it addresses a genuine problem with the whole GLP-1 class.

Weight lost on incretin compounds is not only fat. A meaningful proportion is lean mass — muscle — and that has become one of the sharpest criticisms of the category. Bimagrumab works on the muscle side of that equation rather than the appetite side, and is studied in combination with incretin compounds rather than as a replacement for them.

The distinction, in plain language: if the incretin compounds reduce what goes onto the scales, bimagrumab is aimed at what the scales are actually measuring. Losing twenty kilos is a different outcome depending on what those kilos were. That is a different question from appetite, and it needs a different mechanism to answer it.

How to Read This Field Without Being Swept Along

Three things are worth holding onto as the names multiply.

Newer does not mean better established. The pattern is consistent and worth stating plainly: the compounds with the most receptors have the least long-term human data. Semaglutide has years of post-approval evidence including cardiovascular outcomes. Retatrutide has promising Phase 2 results and open questions. Both facts are true at once.

Headline percentages are not directly comparable. Trials differ in length, population and comparison group. A 16.6% figure at 76 weeks and a 22.5% figure at 72 weeks are not a clean ranking — they are two different experiments. Comparing them properly requires head-to-head trials, which exist for semaglutide and tirzepatide and largely do not yet for the newer compounds.

Approval somewhere is not approval everywhere. Mazdutide is approved in China. That is a genuine regulatory milestone and it says nothing about TGA, FDA or EMA status. These are research-grade compounds and are not approved for human or veterinary use in Australia.

This page reflects the position as of July 2026. This is the fastest-moving area in peptide research, and any page covering it is a snapshot rather than a settled account.

Frequently Asked Questions

Published References

1. le Roux CW, Steen O, Lucas KJ, et al. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” The lancet. Diabetes & endocrinology, 2024. PubMed
   A correction is linked in PubMed. The full correction text was not verified in this review, so its effect on the cited claims remains unresolved. View notice
2. Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.” The New England journal of medicine, 2023. PubMed
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” The New England journal of medicine, 2022. PubMed
4. Heymsfield SB, Coleman LA, Miller R, et al. “Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.” JAMA network open, 2021. PubMed
   Two February 2021 corrections address the Discussion, HbA1c reporting and Table 2. Consult both notices (PMIDs 33576812 and 33646308) before using numerical results. View notice
5. Drucker DJ. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Cell metabolism, 2018. PubMed